The UK and US have secured a important commercial pact that will ensure zero duties on British pharmaceutical shipments going into the American market.
The Terms of the Deal
As part of the deal, the UK has agreed to raise expenditure on drugs through the NHS. This move ensures that import taxes on these key goods will remain at zero for a duration of the next three years.
This agreement follows previous statements to hike tariffs on branded drug products, with increases discussed reaching one hundred percent.
"This arrangement between the Britain bolsters the global environment for new treatments and brings much-needed fairness to transatlantic pharmaceutical trade," a release said.
Trade Importance
Pharmaceuticals represent one of the UK's biggest exports to the US, which is clearly the primary market for large UK drugmakers.
Statistics show that in the year to the end of September, the UK sold medicines totaling £11.1bn to the US. This amount made up nearly one-fifth of all goods exports in that timeframe.
"This agreement secures work, increases funding and facilitates the UK to establish itself as a international leader for biotech and pharma," a minister stated.
Specific British Pledges
The pact involves several specific changes from the British government:
- Revised Affordability Limit: The UK will raise the affordability limit at which it judges new therapies to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to raise total health service expenditure on medicines from 0.3% of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The amount manufacturers must pay back to the NHS to stay within budget will be capped at 15%. Last year, repayments were more than twenty percent.
Broader Context
The pact takes place against a ongoing row between the sector and the ministers over medicine costs and NHS adoption.
These tensions were heightened by assertions that American consumers were charged significantly more for the same drugs than consumers in the Britain and the EU.
In recent months, several large drug company projects in the UK have been halted or abandoned, while substantial investments have been pledged toward projects in the United States.
A senior figure stated that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had decreased as a percentage of its total funding over the past decade.
